Tian Zhang, MD

Adjunct Associate Professor in the Department of Medicine
Campus mail DUMC 103861, Durham, NC 27710
Phone (919) 668-4667
Email address tian.zhang2@duke.edu

Education and Training

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
  • Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
  • M.H.S., Duke University School of Medicine, 2019
  • M.D., Harvard Medical School, 2009

Publications

Schmidt, Andrew L., Matthew D. Tucker, Ziad Bakouny, Chris Labaki, Chih-Yuan Hsu, Yu Shyr, Andrew J. Armstrong, et al. “Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.” Jama Netw Open 4, no. 11 (November 1, 2021): e2134330. https://doi.org/10.1001/jamanetworkopen.2021.34330.

PMID
34767021
Full Text

Kao, Chester, Eric Powers, Yuan Wu, Michael B. Datto, Michelle F. Green, John H. Strickler, Neal E. Ready, Tian Zhang, and Jeffrey M. Clarke. “Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.” Clin Lung Cancer 22, no. 6 (November 2021): 500–509. https://doi.org/10.1016/j.cllc.2021.03.017.

PMID
33972172
Full Text

Koontz, B. F., K. E. Hoffman, T. Oyekunle, D. J. George, T. Zhang, W. R. Berry, W. R. Lee, et al. “Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.” In International Journal of Radiation Oncology, Biology, Physics, 111:e281, 2021. https://doi.org/10.1016/j.ijrobp.2021.07.902.

PMID
34701084
Full Text

Rose, Tracy L., Michael R. Harrison, Allison M. Deal, Sundhar Ramalingam, Young E. Whang, Blaine Brower, Mary Dunn, et al. “Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.” J Clin Oncol 39, no. 28 (October 1, 2021): 3140–48. https://doi.org/10.1200/JCO.21.01003.

PMID
34428076
Full Text

Pal, Sumanta K., Paul H. Frankel, Amir Mortazavi, Matthew Milowsky, Ulka Vaishampayan, Mamta Parikh, Yung Lyou, et al. “Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.” Jama Oncol 7, no. 10 (October 1, 2021): 1536–43. https://doi.org/10.1001/jamaoncol.2021.3441.

PMID
34436521
Full Text

Spees, Lisa, Michaela Ann Dinan, Bradford E. Jackson, Christopher Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah Kaye, et al. “Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.” In Journal of Clinical Oncology, 39:116–116. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2020.39.28_suppl.116.

Full Text

Spees, Lisa P., Stephanie B. Wheeler, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, et al. “Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.” Cancer Med 10, no. 19 (October 2021): 6653–65. https://doi.org/10.1002/cam4.4201.

PMID
34480518
Full Text

Zhu, Shaoming, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li, and Chong-Xian Pan. “Combination strategies to maximize the benefits of cancer immunotherapy.” J Hematol Oncol 14, no. 1 (September 27, 2021): 156. https://doi.org/10.1186/s13045-021-01164-5.

PMID
34579759
Full Text

Brady-Nicholls, Renee, Jingsong Zhang, Tian Zhang, Andrew Z. Wang, Robert Butler, Robert A. Gatenby, and Heiko Enderling. “Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.” Neoplasia 23, no. 9 (September 2021): 851–58. https://doi.org/10.1016/j.neo.2021.06.013.

PMID
34298234
Full Text

Desai, Kunal, Landon Brown, Wei Wei, Matthew Tucker, Chester Kao, Emily Kinsey, Brian Rini, Kathryn Beckermann, Tian Zhang, and Moshe C. Ornstein. “A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.” Target Oncol 16, no. 5 (September 2021): 633–42. https://doi.org/10.1007/s11523-021-00832-3.

PMID
34379283
Full Text

Pages